Dr Eugene Ruzagira, a member of the team of researchers told a news conference organized by the Health Journalists Network that they are giving all the participants in their PrEPVACC trial a daily Descovy tablet to assess whether it’s effective in preventing participants from getting infected.
IP: 126.96.36.199. Referrer: . FirstClickFree: 0. Clicks by IP: ?. Clicks by cookie: ?.